Celldex Therapeutics Inc. (NASDAQ:CLDX) has been assigned a $7.00 price target by investment analysts at Roth Capital in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s target price suggests a potential upside of 58.01% from the stock’s current price.
CLDX has been the subject of a number of other reports. Brean Capital initiated coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $16.00 price target for the company. Zacks Investment Research downgraded Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 price target on shares of Celldex Therapeutics in a research note on Monday, October 10th. Wedbush reaffirmed a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Finally, Jefferies Group raised their price target on Celldex Therapeutics to $5.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Celldex Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $7.44.
Celldex Therapeutics (NASDAQ:CLDX) traded up 1.14% during trading on Wednesday, hitting $4.43. The stock had a trading volume of 892,790 shares. The firm’s market cap is $448.53 million. Celldex Therapeutics has a 52 week low of $2.85 and a 52 week high of $18.56. The company’s 50-day moving average is $3.78 and its 200 day moving average is $4.09.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The company earned $2.20 million during the quarter, compared to the consensus estimate of $1.09 million. During the same period last year, the business earned ($0.32) EPS. The business’s quarterly revenue was up 115.5% on a year-over-year basis. Equities analysts expect that Celldex Therapeutics will post ($1.29) EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Veritable L.P. acquired a new stake in Celldex Therapeutics during the second quarter worth about $132,000. Virginia Retirement Systems ET AL acquired a new stake in Celldex Therapeutics during the third quarter worth about $150,000. Canada Pension Plan Investment Board raised its stake in Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 33,800 shares during the period. AMP Capital Investors Ltd acquired a new stake in Celldex Therapeutics during the third quarter worth about $177,000. Finally, Bank of Montreal Can acquired a new stake in Celldex Therapeutics during the second quarter worth about $188,000. 76.21% of the stock is currently owned by hedge funds and other institutional investors.
About Celldex Therapeutics